Schering-Plough Asmanex
Executive Summary
Dose counter mechanism for mometasone furoate dry powder inhaler "has not been proven to be accurate or reliable," Jan. 19 FDA 483 inspection report states. Manual counts did not match the numbers displayed by the inhaler device's counter, FDA observed. The counting mechanism also exhibited "jamming" and would not decrement as intended. The once-daily corticosteroid has been "approvable" since October 1999 for treatment of asthma in patients 12 and older. The 483 was released by Public Citizen March 1 (1see related story, p. 6)
You may also be interested in...
Schering/FDA Relations Are Priority For Hassan: GMPs, Asmanex On Agenda
Schering-Plough CEO Fred Hassan hopes his credibility with FDA can help in discussions over the company's GMP work plan and the delayed Asmanex approval
Schering/FDA Relations Are Priority For Hassan: GMPs, Asmanex On Agenda
Schering-Plough CEO Fred Hassan hopes his credibility with FDA can help in discussions over the company's GMP work plan and the delayed Asmanex approval
Schering Claritin, Rebetol Await FDA Certification After Consent Decree
Schering-Plough's first batch of products submitted to FDA for certification under a May 16 consent decree will include the Claritin 10 mg dose and the antiviral Rebetol